chr6-129349348-C-T
Variant summary
Our verdict is Benign. Variant got -10 ACMG points: 2P and 12B. PM1BP4_StrongBS1BS2
The NM_000426.4(LAMA2):c.4487C>T(p.Ala1496Val) variant causes a missense change. The variant allele was found at a frequency of 0.00368 in 1,613,554 control chromosomes in the GnomAD database, including 32 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000426.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -10 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00335 AC: 509AN: 152130Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.00373 AC: 937AN: 251380Hom.: 5 AF XY: 0.00384 AC XY: 521AN XY: 135850
GnomAD4 exome AF: 0.00371 AC: 5424AN: 1461306Hom.: 31 Cov.: 30 AF XY: 0.00364 AC XY: 2649AN XY: 726982
GnomAD4 genome AF: 0.00335 AC: 510AN: 152248Hom.: 1 Cov.: 32 AF XY: 0.00310 AC XY: 231AN XY: 74440
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:5
- -
- -
- -
- -
LAMA2: BS2 -
This variant is associated with the following publications: (PMID: 24957499, 28133863, 27854218) -
not specified Uncertain:2Benign:2
Variant summary: LAMA2 c.4487C>T (p.Ala1496Val) results in a non-conservative amino acid change located in the EGF-like domain (IPR000742) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0037 in 1613554 control chromosomes in the gnomAD database V4, including 32 homozygotes. The observed variant frequency is approximately 2 fold of the estimated maximal expected allele frequency for a pathogenic variant in LAMA2 causing Laminin Alpha 2-Related Dystrophy phenotype (0.0022), strongly suggesting that the variant is benign. Although reported in mutational updates (example, Oliviera_2018), to our knowledge, no penetrant association of c.4487C>T in individuals affected with Laminin Alpha 2-Related Dystrophy and no supporting experimental evidence demonstrating its impact on protein function have been reported. The following publication has been ascertained in the context of this evaluation (PMID: 30055037). Nine submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as benign/likely benign (n=5) and VUS (n=4). Based on the evidence outlined above, the variant was classified as likely benign. -
- -
- -
- -
Merosin deficient congenital muscular dystrophy Uncertain:1Benign:1Other:1
GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. -
- -
- -
Muscular dystrophy, limb-girdle, autosomal recessive 23 Pathogenic:1Benign:1
- -
European Non-Finnish population allele frequency is 0.3978%% (rs147077184, 937/251380 alleles, 5 homozygotes in gnomAD v2.1). Based on the classification scheme RMH Modified ACMG/AMP Guidelines v1.5.1, this variant is classified as LIKELY BENIGN. Following criteria are met: BS1 -
Congenital muscular dystrophy due to partial LAMA2 deficiency Uncertain:1
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
LAMA2-related muscular dystrophy Benign:1
- -
LAMA2-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at